Close
American Drug Delivery & Formulation Summit
Xylem

Calixar and University of Avignon to launch new research lab developing innovative chemistry for target discovery

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Shilpa Biologicals Launches Integrated ADC Production Site in India

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd,...

CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing

CPHI Milan 2026, recognized as a premier global gathering...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI...
- Advertisement -

Calixar, the French biotech company specialized in the native isolation of membrane therapeutic targets/antigens and the French University of Avignon-Bio-organic Chemistry and Amphiphilic Systems Team (CBSA) announce the official launch of the CHEM2STAB Laboratory (CHEMistry for STABilization) supported by the French National Research Agency (ANR).

CHEM2STAB is a unique laboratory in the world gathering high-level competencies in chemistry, physical chemistry, biochemistry and structural biology. The main objective of this laboratory is the development of new chemical molecules able to extract and stabilize membrane therapeutic targets without denaturation, and also promoting their crystallization. The discovery of new membrane therapeutic targets is a booming sector implying major challenges in human and animal health.

โ€œRecent socio-economic studies have highlighted the lack of innovation in the pharmaceutical industry, especially in the discovery field. In particular, there is a growing need in the development of new physicochemical processes allowing the structural and functional preservation of complex therapeutic targets. This crucial aspect implemented by CHEM2STAB will have a significant impact on the quality and performance of future drugs and vaccinesโ€, declared Emmanuel Dejean, CEO of Calixar and Co-founder of CHEM2STAB.

โ€œCHEM2STAB will allow us to considerably increase the scientific and economical value of the work conducted at Avignon University. The initiative is aligned with the common objective of gathering private and academic research to facilitate the creation and validation of new chemical compounds with high potential for native membrane protein isolationโ€, explains Grรฉgory Durand, Professor at Avignon University, CBSA Team Manager and Co-founder of CHEM2STAB.

About Calixar
Calixar develops new approaches to isolate in solution – with the highest purity levels – full-length membrane antigens and proteins (GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins), while keeping their structural and functional integrity. Calixarโ€™s approach represents an opportunity for pharmaceutical companies to start and work with high quality targets or antigens before formulating vaccines, developing antibodies, and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. www.calixar.com

About CBSA Team
The Bio-organic Chemistry and Amphiphilic Systems Team (CBSA) is located in The University of Avignon and has been belonging to the French Institute of Biomolecules Max Mousseron (IBMM). The team has a recognized expertise in the synthesis of complex amphiphilic molecules with a specific focus on membrane proteins and the transport of active ingredients. The team has different research collaborations with private as well as academic partners and is set up with facilities of 250mยฒ (laboratory and offices) in a high quality scientific environment.

Press contact
Mr. Lowian Mesnard
+33 (0)481 076 460
lmesnard@calixar.com
www.chem2stab.org

ย 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Biologicals Launches Integrated ADC Production Site in India

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd,...

CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing

CPHI Milan 2026, recognized as a premier global gathering...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI...

Shilpa Biologicals Launches PartnerPower Platform for CDMOs

Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป